Fortress Biotech Soars 13.73% on Menkes Disease Treatment Hopes

On September 5, 2025, Fortress Biotech's stock surged by 13.73% in pre-market trading, marking a significant rise that has caught the attention of investors and analysts alike.

Investors are closely watching Fortress Biotech as the company approaches its PDUFA date of September 30th for its Menkes disease treatment. The anticipation surrounding this regulatory decision has contributed to the recent surge in the stock price, with many investors optimistic about the potential approval of the treatment.

The positive sentiment around Fortress Biotech is also driven by the company's ongoing efforts in the biotech sector. The company's focus on developing innovative treatments for rare diseases has garnered attention and support from the investment community.